These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 8482334)

  • 21. Role of chromosome loss in ras/myc-induced Syrian hamster tumors.
    Oshimura M; Koi M; Ozawa N; Sugawara O; Lamb PW; Barrett JC
    Cancer Res; 1988 Mar; 48(6):1623-32. PubMed ID: 2449958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A study on reversion of the human activated c-Ha-ras-transformed cells].
    Ogiso Y
    Hokkaido Igaku Zasshi; 1988 Sep; 63(5):687-97. PubMed ID: 3071518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.
    Stacey DW; Roudebush M; Day R; Mosser SD; Gibbs JB; Feig LA
    Oncogene; 1991 Dec; 6(12):2297-304. PubMed ID: 1766676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transformation of normal homologous cells by a spontaneously activated Ha-ras oncogene.
    Schwartz SA; Shuler CF; Freebeck P
    Cancer Res; 1988 Jun; 48(12):3470-7. PubMed ID: 3285996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
    Foos G; Hauser CA
    Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
    Kaplan JB
    Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transfection of EK-3, a subline of NIH 3T3, with the oncogene Ha-ras does not abolish its anchorage dependence.
    Katz E; Samid D
    Eur J Cell Biol; 1989 Aug; 49(2):221-4. PubMed ID: 2673787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene.
    Takahashi C; Akiyama N; Matsuzaki T; Takai S; Kitayama H; Noda M
    Oncogene; 1996 May; 12(10):2137-46. PubMed ID: 8668339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis.
    Balmain A; Brown K; Bremner R
    Immunol Ser; 1990; 51():75-88. PubMed ID: 2128916
    [No Abstract]   [Full Text] [Related]  

  • 30. Preneoplastic potential of morphologically distinct transformed foci induced by 3-methylcholanthrene.
    Keshava N; Keshava C; Whong WZ; Hubbs AF; Nath J; Ong T
    Environ Mol Mutagen; 1998; 32(4):369-76. PubMed ID: 9882012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
    Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
    Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The relationship between metastatic phenotype and steady expression of BGC-Ha-ras oncogene from metastasis cell lines in nude mice (abstract)].
    Li YJ
    Zhonghua Zhong Liu Za Zhi; 1992 Nov; 13(6):402-5. PubMed ID: 1349521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tumor suppressor gene WT1 inhibits ras-mediated transformation.
    Luo XN; Reddy JC; Yeyati PL; Idris AH; Hosono S; Haber DA; Licht JD; Atweh GF
    Oncogene; 1995 Aug; 11(4):743-50. PubMed ID: 7651738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.
    Muschel RJ; Williams JE; Lowy DR; Liotta LA
    Am J Pathol; 1985 Oct; 121(1):1-8. PubMed ID: 3901774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
    Castle VP; Dixit VM; Polverini PJ
    Lab Invest; 1997 Jul; 77(1):51-61. PubMed ID: 9251678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
    Kröger A; Dallügge A; Kirchhoff S; Hauser H
    Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
    Chambers AF; Behrend EI; Wilson SM; Denhardt DT
    Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD44 protein levels and its biological activity are regulated in Balb/c 3T3 fibroblasts by serum factors and by transformation with the ras but not with the sis oncogene.
    Kogerman P; Sy MS; Culp LA
    J Cell Physiol; 1996 Nov; 169(2):341-9. PubMed ID: 8908201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Involvement of cAMP dependent protein kinase in the reversion of a NIH/3T3 cell line transformed by a ras oncogene (EJ-NIH/3T3)].
    Oda A
    Hokkaido Igaku Zasshi; 1988 Sep; 63(5):747-53. PubMed ID: 3071519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor rejection antigens on BALB3T3 cells transformed by activated oncogenes.
    Torigoe T; Sato N; Takashima T; Cho JM; Tsuboi N; Qi WM; Hara I; Wada Y; Takahashi N; Kikuchi K
    J Immunol; 1991 Nov; 147(9):3251-8. PubMed ID: 1919013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.